Skip to content
Cardiovascular healthCohort study3 min read

New hypertension diagnoses more than doubled in Italian primary care during the pandemic years

MoveVitals Editorial Collective · Study published · Reading updated

Original paper:Incidence of new-onset hypertension before, during, and after the COVID-19 pandemic: a 7-year longitudinal cohort study in a large population. · BMC medicine · 2024 · Original paper ↗

Key takeaway

In medical records of more than 200,000 adults from a primary care cooperative, new hypertension diagnoses rose from 2.11 per 100 person-years in 2017-2019 to 5.20 in 2020-2022 (RR 2.46) and 6.76 in 2023. Diagnoses are not the same as true new disease, and the data cannot show that COVID-19 itself caused the rise.

Study design

Cohort study

Reading basis

Published abstract

Reading focus

Association & confounding

The research question

COVID-19 is known to raise later diabetes, but evidence on hypertension has been mixed. The authors checked how often new hypertension was diagnosed before, during and after the pandemic in a large closed cohort.

Who and how

Longitudinal cohort study of medical records from a cooperative of primary care physicians, from January 1, 2017, to December 31, 2023, covering 3 years before the pandemic, 3 years during it and 2023. The main outcome was a new diagnosis of hypertension. Incidence was compared between periods, and Poisson regression lines were fitted to monthly log-incidence. The abstract does not name the country or the adjustment used, and the pandemic period was not linked to individual COVID-19 infection status.

What it found

The authors’ reported results. Read each estimate with its population and uncertainty.

  1. 1
    The study evaluated 202,163 people in the pre-pandemic years and 190,743 in the pandemic years, totaling 206,857 including 2023.
  2. 2
    New hypertension incidence was 2.11 per 100 person-years (95% CI 2.08 to 2.15) in 2017-2019, 5.20 (95% CI 5.14 to 5.26) in 2020-2022 and 6.76 (95% CI 6.64 to 6.88) in 2023.
  3. 3
    The pandemic-period rate was 2.46 times the pre-pandemic rate (RR 2.46).
  4. 4
    Poisson models on monthly incidence showed a clearly different trend after the pandemic began, and by the end about 20% of the cohort had developed hypertension, a share higher than the share diagnosed with COVID-19 in the same period.

Limits & uncertainty

  1. 1
    The outcome is a recorded diagnosis, so more checks, more visits or delayed care catching up after lockdowns could raise diagnoses without any change in true disease.
  2. 2
    Because the rise is not tied to individual COVID-19 infection in the abstract, it cannot be attributed to the virus rather than to stress, inactivity, weight gain or health-care changes during the pandemic.
  3. 3
    The data come from one primary care cooperative, so the pattern may not apply to other health systems.
  4. 4
    This reading is based on the abstract only.

What to take from it

The authors suggest hypertension screening should reach the whole population, not only people who know they had COVID-19. If you have not had your blood pressure checked recently, it is reasonable to do so, and any treatment decision belongs with your clinician.

Reading your own data

Home blood pressure with a validated upper-arm cuff is the most direct way to follow this: measure seated and rested at the same time of day, and use averages over several days. Wrist and watch estimates are less reliable, and resting heart rate trends are only a loose complement.

How to read this evidence

Exposure precedes follow-up outcomes, but confounding and reverse causation can remain. A hazard ratio is not an individual absolute risk or a demonstrated intervention effect.

Authors’ structured abstract English

The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.

Background

While the augmented incidence of diabetes after COVID-19 has been widely confirmed, controversial results are available on the risk of developing hypertension during the COVID-19 pandemic.

Methods

We designed a longitudinal cohort study to analyze a closed cohort followed up over a 7-year period, i.e., 3 years before and 3 years during the COVID-19 pandemic, and during 2023, when the pandemic was declared to be over. We analyzed medical records of more than 200,000 adults obtained from a cooperative of primary physicians from January 1, 2017, to December 31, 2023. The main outcome was the new diagnosis of hypertension.

Results

We evaluated 202,163 individuals in the pre-pandemic years and 190,743 in the pandemic years, totaling 206,857 when including 2023 data. The incidence rate of new hypertension was 2.11 (95% C.I. 2.08-2.15) per 100 person-years in the years 2017-2019, increasing to 5.20 (95% C.I. 5.14-5.26) in the period 2020-2022 (RR = 2.46), and to 6.76 (95% C.I. 6.64-6.88) in 2023. The marked difference in trends between the first and the two successive observation periods was substantiated by the fitted regression lines of two Poisson models conducted on the monthly log-incidence of hypertension.

Conclusions

We detected a significant increase in new-onset hypertension during the COVID-19 pandemic, which at the end of the observation period affected ~ 20% of the studied cohort, a percentage higher than the diagnosis of COVID-19 infection within the same time frame. This observation suggests that increased attention to hypertension screening should not be limited to individuals who are aware of having contracted the infection but should be extended to the entire population.

Sources & attribution

Incidence of new-onset hypertension before, during, and after the COVID-19 pandemic: a 7-year longitudinal cohort study in a large population.

Trimarco V, Izzo R, Pacella D, Trama U, Manzi MV, Lombardi A, Piccinocchi R, Gallo P, Esposito G, Piccinocchi G, Lembo M, Morisco C, Rozza F, Santulli G, Trimarco B.

BMC medicine · 2024-03-19

DOI: 10.1186/s12916-024-03328-9 ↗PubMed · 38500180 ↗Europe PMC · Recorded licence: cc by ↗

Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.

MoveVitals editorial interpretation · educational content · no individual clinical review recorded

Sources checked 2026-11-01

Practical guides

Read in context

·Observational meta-analysis

Disrupted daily rest-activity rhythm is linked to higher mortality in 109,365 people

Across seven observational studies with 109,365 participants, a weaker day-night activity contrast (lower relative amplitude) was associated with higher cardiovascular mortality (hazard ratio [HR] 1.50, 95% CI 1.13 to 1.98) and all-cause mortality (HR 1.46, 95% CI 1.27 to 1.68). The evidence base is small and observational, so it cannot show that improving the rhythm lowers risk, and illness may itself disturb the rhythm.

Journal of the American Heart Association

In-depth explainersRead study →
·Trial meta-analysis

Five exercise types lowered resting blood pressure, isometric training the most

Pooling 270 randomised trials with 15,827 participants, aerobic, resistance, combined, interval and isometric training all lowered resting blood pressure compared with non-intervention controls (P<0.001 for each), with the largest fall for isometric training: 8.24 mm Hg systolic and 4.00 mm Hg diastolic. The ranking between modes is partly indirect and the trials differ, so it is not a personal prescription.

British Journal of Sports Medicine

In-depth explainersRead study →
·Randomised trial

A salt substitute lowered stroke, major cardiovascular events and death in rural China

In 20,995 people in 600 rural Chinese villages who had a history of stroke or were 60 or older with high blood pressure, a salt substitute (75% sodium chloride, 25% potassium chloride) lowered the stroke rate versus regular salt over a mean 4.74 years: 29.14 versus 33.65 events per 1000 person-years (rate ratio 0.86, 95% CI 0.77 to 0.96; P = 0.006). Death was also lower (rate ratio 0.88) and serious hyperkalemia events were not significantly higher, but the trial was open-label and set in rural China.

The New England Journal of Medicine

In-depth explainersRead study →
·Validation study/review

Apple Watch irregular-pulse alerts were rare; 34% of those tested had atrial fibrillation

Among 419,297 Apple Watch users with no known atrial fibrillation (AF), 0.52% received an irregular-pulse alert, and 34% of the 450 who returned a usable ECG patch had AF (97.5% CI 29 to 39). Alerts that coincided with patch recording matched AF with a positive predictive value of 0.84 (95% CI 0.76 to 0.92), but only 20.8% of alerted people returned a patch and nobody without an alert was monitored, so a quiet watch does not rule AF out.

The New England Journal of Medicine

In-depth explainersRead study →
Cardiovascular health →